Class I Reimbursement

Thu, 15/04/2010 - 12:35pm -- Inneke Van de Vijver

Hexvix has successfully passed its individual revision of Class I reimbursement.

Hexvix is a porphyrin precursor that is administered intravesically prior to cystoscopy. The product, during its one hour dwelling time is absorbed into the urinary epithelial tissue where it prompts the intracellular accumulation of a photosensitive porphyrin, particularly within neoplastic cells.

Subsequent visualisation of the bladder mucosa with a blue light cystoscope allows the detection of pink-red fluorescent tissue. Hence, fluorescent bladder mucosa becomes a marker for the location of neoplastic tissue which can then be removed by trans urethral resection of the bladder.
Ministerial Decision